EBITDA margin společnosti AC Immune SA
Jaká je hodnota metriky EBITDA margin společnosti AC Immune SA?
Hodnota metriky EBITDA margin společnosti AC Immune SA je 293.05%
Jaká je definice metriky EBITDA margin?
EBITDA margin is a profitability ratio that measures how much EBITDA the company generates as a percentage of revenue.
ttm (trailing twelve months)
EBITDA margin measures how much of EBITDA is generated as a percentage of sales. It measures the company’s operating profit as a percentage of its revenue and is calculated as EBITDA (earnings before interest, taxes, depreciation, and amortization) divided by total revenue.
EBITDA margin also helps with judging the effectiveness of cost-cutting processes at the company. The higher the company’s EBITDA margin, the lower operating expenses are in respect to revenue. As a result, a higher EBITDA margin is considered more favorable. Smaller companies can have higher EBITDA margins since they are able to operate more efficiently and maximize their profitability.
EBITDA excludes interest on debt, taxes, and capital expenditures, the margin does not provide a perfectly clear estimate of the business’s cash flow generation. Furthermore, EBITDA margin is not recognized as a GAAP (generally accepted accounting principles) metric.
EBITDA margin společností v sektoru Health Care sektor na NASDAQ ve srovnání se společností AC Immune SA
Čemu se věnuje společnost AC Immune SA?
ac immune is a clinical-stage swiss-based biopharmaceutical company, listed on nasdaq, which aims to become a global leader in precision medicine for neurodegenerative diseases. the company designs, discovers and develops therapeutic as well as diagnostic products intended to prevent and modify diseases caused by misfolding proteins. ac immune’s two proprietary technology platforms create antibodies, small molecules and vaccines designed to address a broad spectrum of neurodegenerative indications, such as alzheimer’s disease (ad). the company’s pipeline features nine therapeutic and three diagnostic product candidates – with five product candidates currently in clinical trials. the most advanced of these is crenezumab, a humanized anti-amyloid-β monoclonal igg4 antibody that targets monomeric and aggregated forms of amyloid-β, with highest affinity for neurotoxic oligomers. crenezumab is currently in two phase 3 clinical studies for ad, under a global program conducted by the collabor
Firmy s metrikou ebitda margin podobnou společnosti AC Immune SA
- Hodnota metriky EBITDA margin společnosti Western Asset Inflation-Linked Income Fund je 279.93%
- Hodnota metriky EBITDA margin společnosti Banimmo SA je 282.01%
- Hodnota metriky EBITDA margin společnosti Nuveen New Jersey Municipal Value Fund je 284.57%
- Hodnota metriky EBITDA margin společnosti Wellness and Beauty Solutions je 287.70%
- Hodnota metriky EBITDA margin společnosti BP Prudhoe Bay Royalty Trust je 288.86%
- Hodnota metriky EBITDA margin společnosti First Trust Dynamic Europe Equity Income Fund je 289.58%
- Hodnota metriky EBITDA margin společnosti AC Immune SA je 293.05%
- Hodnota metriky EBITDA margin společnosti Norvista Capital je 294.05%
- Hodnota metriky EBITDA margin společnosti abrdn Japan Equity Fund Inc je 294.71%
- Hodnota metriky EBITDA margin společnosti Allied Hotel Properties je 298.57%
- Hodnota metriky EBITDA margin společnosti Gabelli Healthcare & WellnessRx Trust je 301.04%
- Hodnota metriky EBITDA margin společnosti Nuveen California AMT-Free Quality Municipal Income Fund je 301.50%
- Hodnota metriky EBITDA margin společnosti Gabelli Global Small and Mid Cap Value Trust je 301.61%